Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial

Abstract

Background:

The hygiene hypothesis suggests that microbial replacement may be therapeutic in allergic and autoimmune diseases. Nevertheless, the results of helminth treatment, including in multiple sclerosis (MS), have been inconclusive.

Objective:

To assess safety and brain magnetic resonance imaging (MRI) activity in subjects with relapsing-remitting multiple sclerosis (RRMS) during oral administration of ova from the porcine whipworm, Trichuris suis (TSO).

Methods:

A total of 16 disease-modifying treatment (DMT) naive RRMS subjects were studied in a baseline versus treatment (BVT) controlled prospective study. MRI scans were performed during 5 months of screening-observation, 10 months of treatment, and 4 months of post-treatment surveillance.

Results:

No serious symptoms or adverse events occurred during treatment. For the cohort, there was a trend consistent with a 35% diminution in active lesions when observation MRIs were compared to treatment MRIs (p = 0.08), and at the level of individuals, 12 of 16 subjects improved during TSO treatment. T regulatory lymphocytes were increased during TSO treatment.

Conclusion:

TSO is safe in RRMS subjects. Potentially favorable MRI outcomes and immunoregulatory changes were observed during TSO treatment; however, the magnitude of these effects was modest, and there was considerable variation among the responses of individual subjects.

Keywords

Multiple sclerosis helminth therapy hygiene hypothesis phase 1 clinical trial whipworm

Get full access to this article

View all access options for this article.

References

Rook

GA.

Hygiene hypothesis and autoimmune diseases. Clin Rev Allergy Immunol 2012; 42: 5–15.

Stiemsma

Reynolds

Turvey

et al

The hygiene hypothesis: Current perspectives and future therapies. Immunotargets Ther 2015; 4: 143–157.

Maizels

RM.

Parasitic helminth infections and the control of human allergic and autoimmune disorders. Clin Microbiol Infect 2016; 22: 481–486.

Weinstock

JV.

Do we need worms to promote immune health?

Clin Rev Allergy Immunol 2015; 49: 227–231.

Wammes

Mpairwe

Elliott

et al

Helminth therapy or elimination: Epidemiological, immunological, and clinical considerations. Lancet Infect Dis 2014; 14: 1150–1162.

Fumagalli

Pozzoli

Cagliani

et al

Parasites represent a major selective force for interleukin genes and shape the genetic predisposition to autoimmune conditions. J Exp Med 2009; 206: 1395–1408.

Maizels

Balic

Gomez-Escobar

et al

Helminth parasites—Masters of regulation. Immunol Rev 2004; 201: 89–116.

Fleming

Weinstock

JV.

Clinical trials of helminth therapy in autoimmune diseases: Rationale and findings. Parasite Immunol 2015; 37: 277–292.

Lopes

Matisz

Reyes

et al

Helminth regulation of immunity: A three-pronged approach to treat colitis. Inflamm Bowel Dis 2016; 22: 2499–2512.

10.

Matisz

Faz-Lopez

Thomson

et al

Suppression of colitis by adoptive transfer of helminth antigen-treated dendritic cells requires interleukin-4 receptor-alpha signaling. Sci Rep 2017; 7: 40631.

11.

Navarro

Pickering

Ferreira

et al

Hookworm recombinant protein promotes regulatory T cell responses that suppress experimental asthma. Sci Transl Med 2016; 8: 362ra143.

12.

Pineda

Eason

Harnett

et al

From the worm to the pill, the parasitic worm product ES-62 raises new horizons in the treatment of rheumatoid arthritis. Lupus 2015; 24: 400–411.

13.

Smallwood

Giacomin

Loukas

et al

Helminth immunomodulation in autoimmune disease. Front Immunol 2017; 8: 453.

14.

Briggs

Weatherhead

Sastry

et al

The hygiene hypothesis and its inconvenient truths about helminth infections. PloS Negl Trop Dis 2016; 10: e0004944.

15.

Wammes

Hamid

Wiria

et al

Community deworming alleviates geohelminth-induced immune hyporesponsiveness. Proc Natl Acad Sci U S A 2016; 113: 12526–12531.

16.

Tahapary

de Ruiter

Martin

et al

Effect of anthelmintic treatment on insulin resistance: A cluster-randomized placebo-controlled trial in Indonesia. Clin Infect Dis. Epub ahead of print 3 May 2017. DOI: 10.1093/cid/cix416.

17.

Leibowitz

Antonovsky

Medalie

et al

Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation. J Neurol Neurosurg Psychiatry 1966; 29: 60–68.

18.

Fleming

Cook

TD.

Multiple sclerosis and the hygiene hypothesis. Neurology 2006; 67: 2085–2086.

19.

Correale

Farez

MF.

Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 2007; 61: 97–108.

20.

Correale

Farez

MF.

The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol 2011; 233: 6–11.

21.

Fleming

Isaak

Lee

et al

Probiotic helminth administration in relapsing-remitting multiple sclerosis: A phase 1 study. Mult Scler 2011; 17: 743–754.

22.

Benzel

Erdur

Kohler

et al

Immune monitoring of Trichuris suis egg therapy in multiple sclerosis patients. J Helminthol 2012; 86: 339–347.

23.

Voldsgaard

Bager

Garde

et al

Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect. Mult Scler 2015; 21: 1723–1729.

24.

Miller

Albert

Barkhof

et al

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996; 39: 6–16.

25.

Sormani

Miller

Comi

et al

Clinical trials of multiple sclerosis monitored with enhanced MRI: New sample size calculations based on large data sets. J Neurol Neurosurg Psychiatry 2001; 70: 494–499.

26.

Summers

Elliott

Qadir

et al

Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 2003; 98: 2034–2041.

27.

Summers

Elliott

Urban

et al

Trichuris suis therapy for active ulcerative colitis: A randomized controlled trial. Gastroenterology 2005; 128: 825–832.

28.

Bager

Arnved

Ronborg

et al

Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol 2010; 125: 123–130.e1–3.

29.

Polman

Reingold

Banwell

et al

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.

30.

Kurtzke

JF.

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

31.

Cutter

Baier

Rudick

et al

Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122(Pt 5): 871–882.

32.

Tilney

Connelly

Guild

et al

Adaptation of a nematode parasite to living within the mammalian epithelium. J Exp Zool A Comp Exp Biol 2005; 303: 927–945.

33.

Elliott

Summers

Weinstock

JV.

Helminths and the modulation of mucosal inflammation. Curr Opin Gastroenterol 2005; 21: 51–58.

34.

Bundy

Cooper

ES.

Trichuris and trichuriasis in humans. Adv Parasitol 1989; 28: 107–173.

35.

Rook

Lowry

Raison

CL.

Hygiene and other early childhood influences on the subsequent function of the immune system. Brain Res 2015; 1617: 47–62.

36.

Evans

Mitre

Worms as therapeutic agents for allergy and asthma: Understanding why benefits in animal studies have not translated into clinical success. J Allergy Clin Immunol 2015; 135: 343–353.

37.

Sandborn

Elliott

Weinstock

et al

Randomised clinical trial: The safety and tolerability of Trichuris suis ova in patients with Crohn’s disease. Aliment Pharmacol Ther 2013; 38: 255–263.

38.

McKay

DM.

The beneficial helminth parasite?

Parasitology 2006; 132: 1–12.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.14 MB

0.40 MB